Printer Friendly

GLYNASE PRESTAB TABLETS CLEARED FOR MARKETING FOR NON-INSULIN-DEPENDENT DIABETES

 GLYNASE PRESTAB TABLETS CLEARED FOR MARKETING
 FOR NON-INSULIN-DEPENDENT DIABETES
 KALAMAZOO, Mich., March 6 /PRNewswire/ -- The Upjohn Company (NYSE: UPJ) announced today that Glynase PresTab Tablets have been cleared for marketing for the treatment of non-insulin-dependent diabetes and will be introduced shortly.
 Glynase PresTab is an improved formulation of glyburide, the most widely used oral medication in the United States for non-insulin- dependent diabetes, which affects an estimated 14 million Americans. The improved bioavailability (drug delivery) and stability of Glynase PresTab will provide doctors and patients with an optimum glyburide formulation.
 Glynase PresTab is not interchangeable with previous formulations of glyburide due to differences in bioavailability; doctors will need to titrate the dosage of Glynase PresTab with patients' blood sugar levels. The Glynase PresTab tablet has been designed to facilitate this titration by breaking in half easily and consistently if dosage needs to be increased or decreased.
 As a leading cause of death and disability in the United States, diabetes causes personal suffering and more than $20 billion a year in financial costs, creating a continuing need for public awareness of its symptoms and risk factors, education about how to control the disease and improved management of patients.
 The Upjohn Company's founder had non-insulin-dependent diabetes and began the company's diabetes research in the 1920s. Upjohn's commitment to the area of diabetes has included not only medications, but support of nationwide education and public awareness programs to help reach the nearly 7 million people with diabetes who have not yet had their condition diagnosed. Because the disease can begin insidiously and its symptoms can be mistaken for other conditions, it is possible to not have one's diabetes diagnosed until after complications have developed.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 3/6/92
 /CONTACT: Jan R. AufderHeide of Upjohn, 616-323-6546/
 (UPJ) CO: The Upjohn Company ST: Michigan IN: MTC SU: PDT


SB -- DE012 -- 5806 03/06/92 10:49 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 6, 1992
Words:353
Previous Article:IMAGE RETAILING GROUP CHANGES NAME TO AUDIO KING CORPORATION
Next Article:WISTAR INSTITUTE RESPONDS TO ROLLING STONE ARTICLE
Topics:


Related Articles
GLYNASE PRESTAB TABLETS RECEIVE THREE-YEAR MARKETING PROTECTION
BRISTOL-MYERS SQUIBB ACQUIRES U.S. RIGHTS TO GLUCOPHAGE(R), AN ANTIDIABETIC DRUG FROM LIPHA S.A.
COPLEY PHARMACEUTICAL, INC. RECEIVES FDA APPROVAL FOR ATENOLOL TABLETS, 50MG AND 100MG
PRECOSE NOW AVAILABLE FOR TYPE II DIABETES PATIENTS; UNIQUE MECHANISM OF ACTION CREATES NEW TREATMENT PARADIGM
AMARYL(R) FOR TYPE II DIABETES NOW AVAILABLE IN THE U.S.
Clarification: Copley's Micronized Glyburide Is AB Rated, Therapeutically Equivalent To Glynase
First Anti-Diabetic Therapy To Target The Underlying Cause of Type II Diabetes Cleared For Marketing By The FDA
Purdue Pharma L.P. and Kissei Pharmaceutical Co., Ltd. Sign License Agreement for Kissei's Oral Anti-diabetic Compound KAD-1229
Prandin(TM), New Oral Treatment for Type 2 Diabetes, Now Available in the US
Pharmacia & Upjohn Acquires Rights to Antidiabetes Compound

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters